Back to Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 1

Venlafaxine in the treatment of panic disorder

Authors Martin A Katzman, Leslie Jacobs

Published 15 March 2007 Volume 2007:3(1) Pages 59—67

Download Article [PDF] 

Martin A Katzman1,2,3, Leslie Jacobs1

1START Clinic for the Mood and Anxiety Disorders, Toronto, ON, Canada; 2University of Toronto, ON, Canada; 3Northern Ontario School of Medicine, Toronto, ON, Canada

Abstract: Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efficacy and safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side effects that usually abate with continued treatment, venlafaxine is an important option to the SSRIs for the treatment of patients with panic disorder.

Keywords: anxiety disorders, panic disorder, antidepressant therapy, remission, venlafaxine, selective serotonin norepinephrine reuptake inhibitor

Download Article [PDF]